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In the world of cardiovascularmedicine, debates are as common
as unanswered questionsdmedical therapy versus percutaneous
coronary intervention (PCI), drug-eluting stents versus bare-
metal stents, Red Sox versus Yankees.and the list goes on.
The increasing adoption of transradial PCI over the past few
years has led to the inevitable “radial versus femoral” delibera-
tions. In the United States, the predominant approach to PCI
is via the femoral artery (1), and the radial approach is used as
a “bailout” for many operators when they are not able to access
the coronary arteries from either the right or left groin. This
“femoral ﬁrst” paradigm has been solidly in place since the
invention of PCI, and there seemed little reason to question it
until now. Rather than fall into the trap of arguing for one
approach to the exclusion of the other, a more appropriate
question is: Do we have enough evidence to change the
paradigm to a radial ﬁrst, femoral as bailout approach?
Importantly, the concept is not radial instead of femoral,
but rather radial as default. A sea change in the interventional
culture to radial ﬁrst should only occur if the radial approach
is a priori safer than the femoral approach (i.e., the safest
strategy should be the default) and at least as efﬁcacious. Does
the available evidence support this sea change?Bleeding and Vascular Complications
and Associated Outcomes
Risks related to PCI include ischemic events like peri-
procedural myocardial infarction (MI), stent thrombosis,
and stroke, as well as vascular complications including
bleeding. The risk of these events occurring after PCI
are dependent on underlying patient characteristics, the
antithrombotic therapy that is used, the integrity of the
arteriotomy, and the method of post-procedure hemostasis.
In general, the risks are higher as the clinical risk increases,
that is, the risk is lowest among patients undergoing elective
procedures for stable angina, higher among patients with
non–ST-segment elevation acute coronary syndrome (ACS),
and highest among patients with ST-segment elevation
myocardial infarction (STEMI). Among patients under-
going PCI, 30% to 70% of the bleeding complications that
occur are related to the vascular access site (2).Across the spectrum of clinical risk, post-procedural
bleeding and vascular complications have traditionally
been regarded as minor events; however, multiple studies
have shown a strong association between these events and
subsequent morbidity and mortality (3). This is especially
true in patients with ACS. In a study of over 26,000
patients with non–ST-segment elevation ACS, there was
a stepwise increase in the risk of 30-day mortality, 30-day
death or MI, and 6-month mortality as bleeding severity
worsened (4). This association was present for both
procedure- and non–procedure-related bleeding events.
Other outcomes such as stroke (5) and stent thrombosis
(6) also appear to be signiﬁcantly higher among patients
who develop bleeding complications. Blood transfusion,
which has been used liberally in patients with ACS, is also
associated with increased mortality among patients with
ACS (7) and those undergoing PCI (3). In terms
of nonclinical outcomes, studies of ACS and PCI patients
show an association between bleeding and vascular
complications and length of stay and costs (8). A study of
over 335,0000 Medicare patients undergoing PCI showed
that the most commonly recorded complication was
a vascular complication, occurring in 5.47% of patients (more
common than emergency bypass surgery, stroke, or renal
failure combined) (9). After adjustment, each vascular
complication was associated with >$4,000 incremental cost;
given how commonly PCI is performed, this suggests that
over $70 million of U.S. taxpayer money is going to pay for
vascular complications that are potentially preventable.Radial Approach and Complex PCI
In contemporary clinical practice, transradial PCI is associ-
ated with rates of procedure success similar to transfemoral
PCI (1). The radial artery readily accommodates 6-F
sheaths, and sheathless 7-F techniques have recently been
described (10,11). Thus, there is no limitation to
performing complex PCI successfully via the radial
approach. High-risk subsets such as unprotected left main
coronary artery (12) and chronic total occlusions (13) can
all be readily addressed through radial access.
However, effectiveness alone is not enough to change the
paradigm to radial ﬁrst because complex PCI can also be
performed via femoral access. There should be some
advantages of transradial PCI over transfemoral PCI before
it can be recommended as the default approach.
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Compared with the femoral artery, the radial artery is more
superﬁcial, smaller in caliber, lacks any important adjacent
structure or potential spaces (such as the retroperitoneal
space), and is easily compressible. Observational and smaller
randomized trials have found a signiﬁcant reduction in the rate
of major bleeding andmajor vascular access site complications
with radial compared with femoral access in patients under-
going PCI (1,14), even when femoral vascular closure devices
are used (15). The largest and most contemporary trial to
compare radial and femoral access was the RIVAL (RadIal
Vs femorAL access for coronary intervention) trial (14),
which randomized 7,021 ACS patients undergoing
coronary angiography or intervention to either radial or
femoral access. The primary endpoint was a composite of
death, MI, stroke, or major bleeding (deﬁned according to
the CURRENT–OASIS 7 [Clopidogrel and Aspirin
Optimal Dose Usage to Reduce Recurrent Events–Seventh
Organization to Assess Strategies in Ischemic Syndromes 7]
trial) at 30 days. Secondary endpoints included 30-day
death, MI, or stroke, and 30-day non–coronary artery
bypass graft (CABG)-related major bleeding. In addition,
major vascular access site complications, access site
crossover, and patient preference were measured. There was
no signiﬁcant difference between the 2 arms with respect to
the primary outcome (radial 3.7% vs. femoral 4.0%, p ¼
0.50) or the secondary outcomes of death, MI, or stroke
(3.2% vs. 3.2%, p ¼ 0.90) or non–CABG-related major
bleeding (0.7% vs. 0.9%, p ¼ 0.23). Do these results
indicate that radial access is no better than femoral access
and thus the status quo of femoral ﬁrst, radial as bailout
should be maintained?
Let us delve deeper into the RIVAL trial results. As
mentioned, the deﬁnition of non–CABG-related major
bleeding used in RIVAL was the same as was used in the
CURRENT–OASIS 7 trial and is very relevant to an ACS
population: bleeding that was fatal, intracranial, or intra-
ocular leading to signiﬁcant vision loss; required 2 U of
blood transfusion; led to hypotension requiring inotropes;
led to a hemoglobin decrease of 5 g/dl; or required surgical
intervention. However, the deﬁnition does not distinguish
between access-site and non–access-site bleeding. More-
over, the rates of bleeding were signiﬁcantly lower than in
prior ACS studies, and only 32% of the bleeding events
were related to the vascular access site. Therefore, only 0.2%
and 0.3% of the bleeding events in the radial and femoral
groups, respectively, could be attributed to the access site.
This likely reﬂects the expertise of the investigators in
obtaining arterial access regardless of the site. Given these
low event rates, the trial was underpowered to detect
a difference in non–CABG-related major bleeding. By
contrast, major vascular access site complications, an
outcome sensitive to the randomized treatment, were
signiﬁcantly lower among patients assigned to the radialapproach (1.4% vs. 3.7%, p < 0.0001). Moreover, in a post
hoc analysis that assessed the actual location of access site
major bleeding, there were no access site major bleeds in
the radial group compared with 18 in the femoral group.
Combined with other radial versus femoral trials, the ag-
gregate effect of the radial approach is a 65% reduction in
major vascular access site complications, a 49% reduction in
non–CABG-related major bleeding, and a 35% reduction
in the need for transfusion compared with the femoral
approach (14). Given the strong relationship between radial
access and reduced vascular complications, the American
College of Cardiology Foundation/American Heart
Association/Society for Cardiovascular Angiography and
Interventions PCI practice guidelines now give a strong
recommendation to radial approach (16), and the
European Association of Percutaneous Cardiovascular
Interventions group has recently taken the position that it
should be the default access site for PCI (17).
Radial Approach and Nonbleeding Outcomes
Other outcomes worth discussion when comparing radial and
femoral approaches include patient preference, results in
certain patient groups, access site crossover, and costs. In
randomized trials, patients overwhelmingly prefer radial
access to femoral access (14,18). In the RIVAL trial, 90% of
patients assigned to radial access preferred it for their next
procedure compared with only 49% of patients assigned to
femoral who preferred femoral access for a subsequent
procedure (p < 0.0001). This is likely due to the early
ambulation and marked reduction in vascular compli-
cations seen with the radial approach. With respect to
speciﬁc clinical scenarios, patients with STEMI undergoing
primary or rescue PCI are at particularly high risk for bleeding.
A pharmacological strategy, such as bivalirudin, that is
associated with reduced bleeding risk is associated with
a reduction inmortality (19). Recently, the RIFLE-STEACS
(Radial versus Femoral Randomized Investigation in ST-
Elevation Acute Coronary Syndrome) trial was presented
(20). This study randomized 1,001 patients undergoing
primary PCI at 4 experienced radial centers to radial or
femoral access. Compared with femoral access, patients
assigned to radial access experienced a signiﬁcantly lower
rate of Bleeding Academic Research Consortium Type 2
bleeding (12.2% vs. 7.8%, p ¼ 0.026) and signiﬁcantly
lower 30-day cardiac mortality (9.2% vs. 5.2%, p ¼ 0.020).
These data are supported by a meta-analysis of randomized
trials comparing radial and femoral access for PCI in
STEMI patients that demonstrated an association between
transradial primary PCI and reduced mortality, with a slight
increase in procedure time compared with femoral approach
(mean increase 1.76 min) (21).
In the RIFLE-STEACS trial, the rate of access site
crossover overall was 6.1%, with 5.6% of patients assigned to
femoral access crossing over to radial access and 6.8% of
patients assigned to radial access crossing over to femoral
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because of the potential for interpreting the rates as an
indictment of one approach or the other. The body of ev-
idence shows that the rates of access site crossover from radial
to femoral are higher than from femoral to radial (22). In the
RIVAL trial, the rates of crossover from initial radial access
assignment to femoral and vice versa were 7.6% and 2.0%,
respectively. However, in exploratory analyses where
outcomes were analyzed according to the access site used to
complete the procedure, the rates of non–CABG-related
major bleeding were 47% lower with radial access compared
with femoral access (0.6% vs. 1.0%, p ¼ 0.025). Thus,
when transradial PCI can be accomplished successfully,
there is a distinct safety advantage over transfemoral PCI.
Figure 1 displays a proposed initial arterial access algorithm
for patients undergoing PCI. It should be noted that
procedures performed with hemodynamic support devices
(e.g., intra-aortic balloon counterpulsation, Impella
[Abiomed, Danvers, Massachusetts], or TandemHeart
[Cardiac Assist, Pittsburgh, Pennsylvania]) require
concomitant femoral arterial access. Similarly, exceedingly
rare complications that require treatment with a large
covered stent, for example, coronary perforation, will also
require bailout femoral arterial access in order to use large-
bore guiding catheters that can accommodate the device.Figure 1 Proposed Algorithm for Arterial Access in Patients Undergo
Procedures performed with hemodynamic support devices require concomitant femoral arte
example, coronary perforation, will require bailout femoral arterial access in order to use
coronary intervention.Another advantage of radial access is its association with
lower hospital costs. Saﬂey et al. (23) examined procedural and
post-procedural costs among 61,509 femoral and radial
procedures from 2004 to 2009 in a large administrative
database and found that, whereas radial procedures were
associated with $17 higher procedural costs, post-procedure
costs were $478 to $917 lower for radial procedures. These
savings were driven by reduced length of stay among
patients undergoing transradial PCI. Coupled with studies
showing a strong patient preference for radial access, the
data support a signiﬁcant beneﬁt of transradial procedures
on outcomes other than clinical endpoints.Does the Evidence Support a Radial First,
Femoral as Bailout Approach?
Deciding between 2 therapeutic strategies involves weighing
the risks and beneﬁts of each. However, the decision
between radial and femoral access for PCI does not involve
the choice of one at the exclusion of the other. Although the
default vascular access for PCI has traditionally been via the
femoral artery, the bulk of evidence calls for a re-evaluation of
this dogma. PCI-related bleeding and vascular complications
are associated with increased morbidity, mortality, and costs.
The evidence consistently shows that, compared with theing PCI
rial access. Procedural complications that require treatment with a covered stent, for
large-bore guiding catheters that can accommodate the device. PCI ¼ percutaneous
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patients, associated with reduced mortality in primary PCI,
and is associated with lower hospital costs. Therefore, in the
modern era of PCI, radial access is preferred, and femoral
access should be used as a bailout strategy.
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Perspective:
Femoral Access Is Preferred
Don’t Throw the Femoral
Out With the Bathwater
Zoltan G. Turi, MD,* S. Chiu Wong, MDy
In the current radial–femoral debate, the rush to transradial
access (TRA), much delayed in the United States, though
long embraced in the rest of the world, may result in a loss of
perspective on the beneﬁts of femoral access. An increasing
minority of laboratories and individual operators are ex-
posing patients to a long learning curve; additional procedure
time, radiation, and morbidity; and in some cases, decreased
quality of diagnostic angiograms as well as interventions. We
believe that femoral remains the preferred technique in
a variety of settings, with as yet an incomplete evidence
base for the overall superiority of the radial approach.
After Seldinger (1) introduced his percutaneous arterial
access technique, the introduction of catheters was vastly
simpliﬁed, and the complications associated with cutdowns
were dramatically reduced. Nevertheless, the initial cardiac
and coronary catheterizations were done through the arm,
via open brachial access, and the 2 methods competed
for primacy through the 1970s. Eventually, the brachial
approach for routine cardiac catheterization was largely
abandoned, and there are lessons that are applicable to
TRA: the speed, simplicity, and ﬂexibility provided by
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of the intrinsic limitations of the brachial approach apply to
TRA as well, in particular the 50% to 70% smaller size of the
radial artery than the typical femoral.
But, the generic issues of arm access are worth empha-
sizing, and these apply equally to radial as well as brachial
access. First, access to the coronary arteries, usually trivial via
transfemoral access (TFA), requires 3 distinct steps: 1)
arterial access; 2) negotiating the catheter to the ascending
aorta; and 3) intubating the coronary arteries. We maintain
that each of these steps is more difﬁcult, more time
consuming, and more likely to fail or be inadequate with
TRA. Ample evidence comes from the RIVAL (RadIal Vs
femorAL access for coronary intervention) trial of 7,021
patients randomized to TRA versus TFA (2); access failure
occurred in 7% of radial cases versus 0.9% of femoral when
there was protocol adherence. Second, once coronary access
is secured, the quality of the procedure is more likely to
be compromised by inadequate support or visualization.
Although, with proper training and experience, many if
not most of these issues can be surmounted, there is a far
greater learning curve (3) with TRA, and as is always the
case with learning curves, a signiﬁcant percentage of
practitioners may never reach the plateau required for
results comparable to what they would achieve much more
easily via the femoral route. Further, we do not believe the
learning curve issue will be resolved as long as we continue
to have substantial numbers of low-volume operators as
well as trainees. Third, the ﬂexibility in terms of catheter
sizes and procedures inherent in access to a large vessel
cannot be achieved via TRA, no matter the operator’s skill
and experience. Fourth, the longer time and greater
radiation (both for the patient and the operator) inherent
in radial access (4) when performed by all but the most
experienced and highest-volume operators are important
points in favor of the femoral approach. We concede
a ﬁfth point, that closure is generally simpler, cheaper, and
potentially safer via the radial route, but even on this issue,
there are some potential concerns, in particular the loss of
arterial patency in a signiﬁcant percentage of radials.
Access
Most operators using traditional landmarks can access the
femoral artery with great facility and speed; failure to access
a patent femoral artery is uncommon. Use of comprehensive
ﬂuoroscopic or ultrasound guidance can optimize puncture
below the inguinal ligament and above the femoral bifur-
cation without signiﬁcant compromise in time to sheath
placement. Much of the debate regarding complications of
femoral versus radial access compares radial access to tradi-
tional landmark-guided femoral access onlydwe maintain
that if micropuncture and adjunctive ﬂuoroscopy or ultra-
sound were used effectively in these studies, the complica-
tion differences would be minimal, though this hypothesis
has not been adequately tested (5). Regardless, radial accessis an art form that, even in the most skilled of hands, has
a higher failure rate and longer access time than femoral.
As a result, even though the most compelling evidence
base clearly demonstrates the superiority of TRA only in
the setting of ST-segment elevation myocardial infarction
(2), many radial operators still prefer the femoral approach
in order to minimize door-to-balloon times.
Negotiating to the Ascending Aorta
In typical patients, the iliac system provides little if any
impediment to access the aorta. Even in patients with
signiﬁcant vascular disease, access can usually be achieved.
By contrast, traversing the arm requires skill in overcoming
obstacles that are rare in the iliacdspasm; intrinsically small
vessel size; blind alleys such as accessory radial branches,
severe tortuosity, and complete loops; entry into small side
branches that can result in perforation and compartment
syndrome; and any number of other hazards that may be
found even in patients without vascular disease per se.
Further along, tortuous subclavians, including the lusoria
anomaly, can make access difﬁcult and sometimes impos-
sible, or even when achieved, impair torquability to such an
extent that the procedure cannot be completed. In general,
deploying in the ascending rather than descending aorta,
although readily achievable in most cases, requires additional
effort usually not required in the femoral approach. How
often is each of these factors responsible for failure to reach
the ascending aorta? Data from a subset of 3,190 patients
in the RIVAL trial included failure of TRA due to radial
spasm in 5.0%, radial artery loop in 1.3%, and subclavian
tortuosity in 1.9%. By contrast, iliac tortuosity accounted for
failure in only 0.6% of patients, as did peripheral vascular
disease in the femoral cohort. The results did not describe
failure to enter the radial artery, but initial entry can be time
consuming and adds signiﬁcantly to the failure rate. Finally,
manipulating under the vertebral artery in the subclavian and
under the common carotid artery adds embolic hazards,
either from plaque and atheroma disruption or clot forming
on guidewires and catheters. Emboli by transcranial Doppler
are substantially more frequent via the radial than the
femoral route (6). In a recent randomized comparison of
TRA versus TFA for diagnostic catheterization in patients
with aortic stenosis, diffusion-weighted magnetic
resonance imaging showed a nonsigniﬁcant trend toward
higher cerebral infarction rates in patients undergoing
TRA (17.5% vs. 11.7%, p ¼ 0.31) in a study that was
underpowered (7).
Coronary Intubation
Somewhat surprisingly, pre-formed catheters that spring readily
into the coronary arteries via the femoral route are used in the
majority of radial cases as well (8), despite limitations that make
them potentially inferior in terms of access and backup when
deployed transradially. Although catheters have been designed
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been an elusive goal since the early days of the Sones brachial
approach. The need for such a catheter is minimal via the
femoral route because removal of one catheter and placement
of another is usually trivial. However, via the radial, repeat
negotiation of the catheter from the radial to the ascending
aorta is undesirable for the reasons already described. Thus, an
exchange technique is usually used for subsequent catheters,
a somewhat tedious process that includes additional risk of
spasm and, more importantly, embolization, especially when
wire exposure under the cranial vessels is prolonged. Although
many of the problems of coronary intubation can be addressed
by access via the left radial, 90% of operators use the right (8);
the latter is associated with decreased torquability and
substantial loss of mechanical backup force (9), in particular
for left coronary interventions.
Quality
The limitations imposed by the smaller size of the radial
artery incline users to smaller diagnostic and interventional
catheters. Although using power injectors and more sensitive
x-ray equipment can improve coronary visualization, the
combination of smaller catheters and more difﬁculty in
selective cannulation results in poorer quality imaging in
some cases, particular in less experienced hands. Maneuvers,
such as taking a deep breath, that improve angiographic
quality by displacing the diaphragm from the ﬁeld and
slowing contrast transit time, can dislodge TRA coronary
catheters.
Time and Radiation
Although conceding that both of these parameters are
substantially inﬂuenced by operator learning curves, both
procedure time and radiation are generally greater via the
radial approach (10). Even in the RIVAL trial, ﬂuoroscopy
times were statistically signiﬁcantly longer with radials.
We concede that vascular complications and bleeding are
more frequent with TFA, although analysis of the latter is
confounded by variable deﬁnitions and by inconsistent ﬁndings
of various subgroup analyses (11,12). We believe the rate of
TFA complications is signiﬁcantly dependent on the less
than optimal access techniques used bymany femoral operators.
With improved access and better anticoagulation regimens,
arguably in combination with vascular closure devices, data
suggest a continuing decrease in femoral access site complica-
tions (13), including bleeding. And although bleeding is
independently associated with adverse outcomes, only a
minority of major bleeds are directly related to the femoral
access site (14). In addition, some admittedly uncommon
complications of radial access virtually never occur with
femoral access: arm compartment syndrome and inability to
extract the catheter or avulsion of the radial. Studies of the
stroke issue as previously discussed have been underpowered
and thus are inconclusive, but the results to date remainconcerning for excess stroke risk with TRA. We would add
that the loss of radial artery patency in up to 12% of cases at
24 h (15) is not a “victimless crime” (though several
techniques to preserve radial ﬂow improve this, in particular
the patent hemostasis technique). The need to preserve the
radial artery is a subtle but important issue: for subsequent
catheterizations, possibly for providing radial artery grafts, and
perhaps for patients who will someday require dialysis.
Although patients prefer the early ambulation and limited
immobility associated with radial access, some experience
severe pain during catheter manipulation, in particular when
there is spasm of the radial and brachial arteries. Finally, the
theoretical advantage of early ambulation with TRA can be
addressed with vascular closure devices, admittedly at greater
cost and some additional risk.
Those arguing in favor of TRA usually cite the effects of
experience and optimal techniques as substantial mitigating
factors for its limitations, an argument that has been used in
behest of both the radial (16) and femoral approaches (as we
have in this paper). Thus, although the RIVAL trial failed to
show overall superiority of TRA for the primary outcome,
the highest tercile of TRA experience did favor radial (2).
It should be noted that even in this subgroup, the
crossover rate had a hazard ratio of 1.9 (p ¼ 0.007)
favoring the femoral approach. And the majority of
catheterizers do not meet the criteria for the highest tercile
experience of the RIVAL trial: in a meta-analysis of 2,460
patients by Jolly et al. (17), those not deemed “experts”
had a 3.5-fold higher rate of inability to cross with wire,
balloon, or stent via the radial approach. Not measured by
such studies is the ﬂexibility inherent in femoral access,
including the ability to place intra-aortic balloon pumps as
well as devices >20-F, whereas even 8-F may be
a challenge via the radial artery.
In the real world, we have watched our colleagues, even
those who are highly experienced, occasionally struggle
with access, angiography, and interventions because of
limitations of the radial approach. For those of us who have
converted to radial (Z.G.T.) and choose to do the occa-
sional femoral case, it is like rediscovering an old friend-
dsimple access to both the artery and the coronaries,
excellent backup support for interventions, and ﬂexibility in
choosing devicesdthese all seem like rediscovered plea-
sures in the catheterization laboratory. We think that in the
rush to embrace radials, we should remember the advan-
tages of the femoral approach, continue to utilize it in
a signiﬁcant percentage of patients, and not throw out
a reliable and well-established technique with the prover-
bial bathwater.Reprint requests and correspondence: Dr. Zoltan G. Turi,
Cooper University Hospital, Cooper Vascular Center, Cooper
Medical School of Rowan University, One Cooper Plaza D-427,
Camden, New Jersey 08103. E-mail: Turi-zoltan@cooperhealth.edu.
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The Ongoing Debate Between
“Femoralists” and “Radialists”
Should There Be a Default Strategy?
Sorin J. Brener, MD,*y Gregg W. Stone, MDyz
As more complex invasive procedures are performed in
patients with increasing comorbidities, there is a compelling
need to develop approaches to make these procedures safer
(for patient and operator), more efﬁcient, and more
comfortable. Improvements in equipment, modiﬁcations in
adjunctive therapies, and enhanced imaging have improved
outcomes and have reduced complications associated with
the invasive nature of coronary diagnostic and therapeutic
procedures. Arguably, the adoption of transradial access
(TRA) has been 1 of the principal advancements in this
quest.
In this issue of the Journal, 2 perspectives illuminate the
controversy surrounding the preferred access site for coronary
imaging and intervention. Dr. Rao elegantly proposes that
TRA has matured to the point where it should be the default
strategy for diagnostic cardiac catheterization and percuta-
neous coronary intervention (PCI). In a counterperspective,
Drs. Turi and Wong argue as convincingly that there are still
many reasons why transfemoral access (TFA) should not be
discarded in the rush to adopt a still incompletely tested
paradigm.
Although we ﬁnd both viewpoints compelling, the
present commentary will clarify some of the essential
elements of the 2 approaches, without repeating the argu-
ments already made.
The TRA Learning Curve
A learning curve refers to the ability of operators to gain
proﬁciency as they repeatedly perform a certain task. As
none of us is born knowing how to perform diagnostic and
therapeutic cardiac catheterization, it is obvious that such
a curve would exist for both TFA and TRA. As long as it is
reasonable in length and predictable in its apogee, the
existence of a learning curve should not be an argument
against TRA. On the contrary, if TRA is indeed superior to
TFA, we should intensify the exposure of trainees and
certiﬁed operators to TRA and render everyone competent
as soon as possible. Ball et al. (1) recently studied this issue
in a rigorous fashion among 28 operators performing the
ﬁrst 1,628 PCI procedures by TRA at their institutions.
PCI failure was inversely related with volume (p ¼
0.003), and there was a 32% decrease in failure rates for
every additional 50 procedures performed. Optimistically,
they concluded that a case volume of at least 50 PCIs is
required to achieve proﬁciency similar to that of
experienced operators (>300 cases). However, even when
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and contrast than TFA operators. Failure to access the
coronary arteries remains unpredictable, even in the most
experienced hands (2). Before the very large RIVAL (A
Trial of Trans-radial Versus Trans-femoral Percutaneous
Coronary Intervention [PCI] Access Site Approach in
Patients With Unstable Angina or Myocardial Infarction
Managed With an Invasive Strategy) trial, 23 randomized
clinical trials had been performed comparing the 2 access
strategies, encompassing >7,000 patients. Meta-analysis
of these moderate-size trials suggested that compared with
femoral access, radial access reduces the composite of
death, myocardial infarction (MI), or stroke (hazard ratio
[HR]: 0.71; 95% conﬁdence interval [CI]: 0.49 to 1.01)
and major bleeding (according to trial deﬁnition) (HR:
0.27; 95% CI: 0.16 to 0.45), although at the cost of
a marginally higher rate of failure to complete the PCI
procedure (HR: 1.31; 95% CI: 0.87 to 1.96) (3).
As is not uncommon, the results of this meta-analysis were
“overturned” by RIVAL (6), a dedicated large-scale
randomized trial performed in 7,021 patients with acute
coronary syndromes undergoing angiography (with PCI in
66%) enrolled from 158 hospitals in 32 countries. The
RIVAL trial demonstrated nonsigniﬁcant differences
between TRA and TFA in the 30-day rates of composite
death, MI, or stroke (3.2% in both groups, p ¼ 0.90); non–
coronary artery bypass graft–related major bleeding (0.7% vs.
0.9%, p ¼ 0.73); or transfusions (1.1% vs. 1.3%, p ¼ 0.51).
There was also no signiﬁcant interaction by operator TRA
volume and a randomized arm on the outcomes of composite
ischemic plus bleeding events (although a borderline
signiﬁcant interaction unadjusted for the number of
comparisons was present between outcome and center
volume). Moreover, despite the fact that RIVAL enrolled
experienced radial operators (median 300 PCI procedures
per year; 40% TRA), crossover from TRA to TFA was
required in 7% of patients, most commonly for radial artery
spasm, radial artery loop, and subclavian tortuosity. In
contrast, crossover from TFA to TRA was required in only
0.9% of patients (p < 0.0001). Thus, at least based on the
most contemporary evidence-based deﬁnitive trial, there
would not seem to be an overwhelming societal need to train
all operators in TRA (to the exclusion of TFA), although the
door remains open as to whether improved outcomes might
be obtained at the most experienced centers (and, intuitively,
by the most experienced operators).
The reasons why RIVAL did not achieve its goal of
showing superiority of TRA over TFA deserve a deeper look
and hinges on the relationship between bleeding, vascular
complications, and mortality.
Bleeding and Vascular Access Complications
The relationship between (major) bleeding complications
and subsequent death in patients undergoing PCI has
been demonstrated in numerous studies, particularly in thesetting of acute coronary syndromes (5). Importantly, many of
the risk factors that predispose patients to bleeding
also increase their risk of ischemic events, placing the
treating physician in a difﬁcult predicament (6). Although
vascular access complications can occur during both
diagnostic and interventional procedures, major bleeding
occurs predominantly with the latter. However, at least one-
half of these bleeding episodes are related to systemic
anticoagulation and occur remotely from the access site;
thus, they cannot be modiﬁed by changing the vascular
access site (7). After PCI in ST-segment elevation
myocardial infarction (STEMI), the proportion of access-
site bleeding may be closer to 50% of all episodes, whereas
in elective PCI, two-thirds of hemorrhagic complications
occur remotely from the vascular access site. In a recent
analysis from the National Cardiovascular Data Registry,
greater use of bivalirudin and vascular closure devices
(VCDs) was associated with a marked reduction in the
incidence of major bleeding and vascular access
complications (10). In this study of >1.5 million
procedures, the rate of major bleeding was 2%. VCDs,
bivalirudin, or both were used in 24%, 23%, and 18%,
respectively, of the cohort. Bleeding was noted in 2.8% of
those in whom manual compression was used after heparin-
supported PCI, and in 2.1%, 1.6%, and 0.9% when VCD,
bivalirudin, or both were used; this is, an impressive 70%
reduction in risk with the combination of pharmacological
and mechanical bleeding avoidance strategies. When
patients were characterized by the National Cardiovascular
Data Registry bleeding risk model, those at the highest risk
had a 65% risk reduction when VCDs and bivalirudin were
used (from 6.1% with manual compression and heparin to
2.3%). Although these data do not stem from randomized
clinical data, the associations remained valid after propensity
matching and provide a credible snapshot of clinical practice
in the United States. Finally, the association between major
bleeding and death is far greater for nonaccess site bleeds
than for access site bleeds (9,10). Indeed, in the ABOARD
(Angioplasty to Blunt the Rise of Troponin in Acute
Coronary Syndromes Randomized for an Immediate or
Delayed Intervention) trial (11), despite nearly universal use
(85%) of TRA, major bleeding still occurred in 5.4% of
patients (80% nonaccess site) and was associated with
increased mortality at 1 month (26.3% vs. 0.6% in those
without major bleeding, p < 0.001).
Back to RIVAL. Among the >7,000 patients enrolled in
this trial, there were only 18 cases (0.2%) of major bleeding
related to the access site (12 in the TFA group and 6 in the
TRA group, the latter because of a switch to TFA after
failure of TRA) (4). Not surprisingly, therefore, by
intention-to-treat, the rates of Thrombolysis In
Myocardial Infarction (TIMI) major bleeding were similar
between the 2 groups, although there were signiﬁcantly
more vascular access complications (large hematoma,
pseudoaneurysm requiring closure, arteriovenous ﬁstula, or
other vascular surgery related to the access site) in the
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patients in the TFA group, and bivalirudin was used as
the procedural anticoagulant in <3% of patients.
Moreover, it is important to discern which types of
bleeding actually inﬂuence late mortality. Using 3 large
contemporary trial databases in which patients with stable
ischemic heart disease, non–ST-segment myocardial
infarction (NSTEMI), and STEMI were enrolled, Mehran
et al. (9) showed that although numerous deﬁnitions of
major bleeding were strongly associated with subsequent
mortality, isolated large hematomasdthe predominant
difference between TRA and TFAddoes not affect
mortality (9). In this study, TIMI major bleeding was
associated with a nearly 5-fold increase in mortality, and
even transfusion without major bleeding carried a nearly 3-
fold higher risk of death. Using the same studies,
Verheugt et al. (7) showed that 61% of all TIMI major
bleeding episodes after TFA were not related to access site
and that bivalirudin reduced the incidence of these events
by w40%, both at the access site and systemically.
Remarkably, however, the impact of non–access-site
bleeding on subsequent 1-year mortality was signiﬁcantly
more pronounced than that of access-site bleeding (HR:
3.94 vs. 1.82, respectively), possibly reﬂecting the
magnitude of blood loss. Similarly, in the STEEPLE
(Safety and Efﬁcacy of Intravenous Enoxaparin in Elective
Percutaneous Coronary Intervention: An International
Randomised Evaluation) trial, large hematomas did not
affect either 30-day outcomes or 1-year mortality (12).
Finally, examining the results at a single high-volume
institution, Applegate et al. (13) showed that vascular
access complications did not affect the rates of 30-day or
1-year MI or death, unless they were associated with
major bleeding.
Is TRA Particularly Beneﬁcial in STEMI?
One of the more intriguing observations from recent trials
comparing TRA with TFA was the suggestion that
mortality can be reduced in STEMI patients treated with
primary PCI when TRA is used. In the recently published
RIFLE STEACS (Radial Versus Femoral Randomized
Investigation in ST Elevation Acute Coronary Syndrome)
study, 1,001 patients with STEMI were randomly assigned
to TRA or TFA (14). There were no differences in total
ischemic time, use of glycoprotein IIb/IIIa inhibitors
(69%), thrombus aspiration (41%), or ﬁnal TIMI ﬂow
grade 2 to 3 (96%) between the groups. Yet, the incidence
of death was markedly lower in the TRA group (5.2% vs.
9.2%, p ¼ 0.02). Access-site bleeding was 62% lower in
the TRA arm (2.6% vs. 6.8%, p ¼ 0.002), and there were
no differences in non–access-site bleeding (5.2% and 5.4%,
respectively). Consistent with these data, a subgroup
analysis from RIVAL (although methodologically unsound
because it was derived from a trial which did not meet its
primary endpoint) found a signiﬁcant interaction betweenclinical presentation and access site, such that there was
a beneﬁt for TRA compared with TFA in STEMI
patients and a neutral effect in NSTEMI (p for
interaction ¼ 0.025, unadjusted for multiple subgroups)
with respect to the composite outcome of death, MI,
stroke, or major bleeding. It is important to note, however,
that in both of these trials, the absolute reduction in major
bleeding with TRA was smaller than the overall reduction
in death or major adverse cardiovascular events (!),
suggesting that the play of chance was involved in these
observations. We completely support the recent
recommendations in the position paper of the European
Association of Percutaneous Cardiovascular Interventions
and Working Groups on Acute Cardiac Care and
Thrombosis of the European Society of Cardiology that
implementation of TRA in STEMI should be reserved as
the last step of a carefully monitored program of transition
from TFA, after all-comer PCI and complex PCI have
been performed via this access route (15).Summary
The data and concepts discussed in the 2 perspectives and in
our commentary lead us to the following observations and
recommendations:
1. There is little doubt that major bleeding after diag-
nostic and interventional procedures is strongly and
independently associated with adverse outcomes via
a host of putative mechanisms. Prevention of these
complications is an essential goal for practitioners and
an important target for quality improvement projects.
2. The majority of prognostically signiﬁcant bleeding
episodes do not arise from the access site and thus
cannot be modiﬁed by the route of vascular access. It is
thus unlikely that a major survival advantage would be
realized by choosing TRA rather than TFA (or vice
versa). Other bleeding avoidance strategies, such as the
use of bivalirudin (for PCI with both radial and
femoral vascular access), avoidance of potent anti-
platelet agents in patients in whom the risk of bleeding
is likely to be greater than the anti-ischemic beneﬁt,
and possibly the use of VCDs if TFA is selected
(acknowledging that a contemporary randomized trial
is needed to validate recent favorable ﬁndings for these
devices), are more likely to improve outcome.
3. Undoubtedly, TRA results in faster time to ambula-
tion and, in most cases, less discomfort at the access
site; also, many patients prefer TRA to TFA. TRA is
also clearly preferred for morbidly obese patients and
for most patients with severe peripheral vascular
disease. However, TRA is more likely to be associated
with greater radiation exposure (especially to the
operator), may result in radial artery occlusion and
other complications, and is associated with crossover
to TFA not infrequently, which may affect door-to-
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to large sheaths and devices (as well as hemodynamic
support device use and venous access), provides
superior guide support in many patients, and is the
easier route from which to cannulate saphenous vein
bypass graft conduits. Thus, both the TRA and the
TFA are important for the expert interventionalist to
master. Interventional fellowship programs should
provide training in both approaches.
4. High-volume operators (>150 PCI/year) should
maintain proﬁciency in both TRA and TFA and
select the optimal route of vascular access according to
the patient’s indication for procedure, the likelihood of
requiring large sheaths or anticipated difﬁculty with
guide support, the presence of obesity and peripheral
vascular disease, and the complexity of PCI. Lower-
volume operators should concentrate on 1 access route
predominantly (either TRA or TFA) and optimize
their performance with that approach in the context of
a rigorous quality assurance program.Reprint requests and correspondence: Dr. Sorin J. Brener,
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